Literature DB >> 30228955

Inflammation drives nitric oxide synthase 2 expression by γδ T cells and affects the balance between melanoma and vitiligo associated melanoma.

Laetitia Douguet1,2,3, Lloyd Bod1,2,3, Laura Labarthe1,2,3, Renée Lengagne1,2,3, Masashi Kato4, Isabelle Couillin5, Armelle Prévost-Blondel1,2,3.   

Abstract

The high expression of inducible nitric oxide synthase (NOS2) by myeloid-derived suppressor cells (MDSCs) is a key mechanism of immune evasion in cancer. Recently we reported that NOS2 is also expressed by γδ T cells in melanoma, contributing to their polarization towards a pro-tumor phenotype. The molecular mechanisms underlying regulation of NOS2 expression in tumor-induced γδ T cells remain unexplored. By using the model of mice transgenic for the ret oncogene (Ret mice) that develops a spontaneous metastatic melanoma, we evidence that interleukin (IL)-1β and IL-6 drive NOS2 expression in γδ T cells. Indeed, their in vivo neutralization lessens the γδ T cell capacity to produce not only NOS2, but also IL-17 involved in the recruitment of MDSCs at the primary tumor site. The treatment also delayed tumor cell dissemination and induced vitiligo in a significant proportion of Ret mice. Interestingly, Ret mice developing a less aggressive melanoma, characterized by the spontaneous development of a concomitant autoimmune vitiligo, exhibit a weaker concentration of inflammatory cytokines and a reduction of tumor infiltrating γδ T cells expressing NOS2, when compared to Ret mice without any signs of vitiligo. Overall our results support that the level of inflammation at the tumor site regulates NOS2 expression by γδ T cells and the development of vitiligo associated melanoma.

Entities:  

Keywords:  NOS2; interleukin 1β; interleukin 6; melanoma; pro-tumorogenic γδ T cells

Year:  2018        PMID: 30228955      PMCID: PMC6140581          DOI: 10.1080/2162402X.2018.1484979

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  40 in total

1.  Arginase regulates red blood cell nitric oxide synthase and export of cardioprotective nitric oxide bioactivity.

Authors:  Jiangning Yang; Adrian T Gonon; Per-Ove Sjöquist; Jon O Lundberg; John Pernow
Journal:  Proc Natl Acad Sci U S A       Date:  2013-08-26       Impact factor: 11.205

2.  SETD1B Activates iNOS Expression in Myeloid-Derived Suppressor Cells.

Authors:  Priscilla S Redd; Mohammed L Ibrahim; John D Klement; Sarah K Sharman; Amy V Paschall; Dafeng Yang; Asha Nayak-Kapoor; Kebin Liu
Journal:  Cancer Res       Date:  2017-04-05       Impact factor: 12.701

Review 3.  Neutralizing tumor-promoting chronic inflammation: a magic bullet?

Authors:  Lisa M Coussens; Laurence Zitvogel; A Karolina Palucka
Journal:  Science       Date:  2013-01-18       Impact factor: 47.728

4.  Spontaneous vitiligo in an animal model for human melanoma: role of tumor-specific CD8+ T cells.

Authors:  Renée Lengagne; Frédérique-Anne Le Gal; Marylène Garcette; Laurence Fiette; Patrick Ave; Masashi Kato; Jean-Paul Briand; Christian Massot; Izumi Nakashima; Laurent Rénia; Jean-Gérard Guillet; Armelle Prévost-Blondel
Journal:  Cancer Res       Date:  2004-02-15       Impact factor: 12.701

Review 5.  Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment.

Authors:  Katherine H Parker; Daniel W Beury; Suzanne Ostrand-Rosenberg
Journal:  Adv Cancer Res       Date:  2015-05-12       Impact factor: 6.242

6.  Transgenic mouse model for skin malignant melanoma.

Authors:  M Kato; M Takahashi; A A Akhand; W Liu; Y Dai; S Shimizu; T Iwamoto; H Suzuki; I Nakashima
Journal:  Oncogene       Date:  1998-10-08       Impact factor: 9.867

7.  Prognostic significance of autoimmunity during treatment of melanoma with interferon.

Authors:  Helen Gogas; John Ioannovich; Urania Dafni; Catherine Stavropoulou-Giokas; Konstantina Frangia; Dimosthenis Tsoutsos; Petros Panagiotou; Aristidis Polyzos; Othonas Papadopoulos; Alexandros Stratigos; Christos Markopoulos; Dimitrios Bafaloukos; Dimitrios Pectasides; George Fountzilas; John M Kirkwood
Journal:  N Engl J Med       Date:  2006-02-16       Impact factor: 91.245

Review 8.  γδ T cells in cancer.

Authors:  Bruno Silva-Santos; Karine Serre; Håkan Norell
Journal:  Nat Rev Immunol       Date:  2015-10-09       Impact factor: 53.106

9.  Crucial role of inflammatory monocytes in antitumor immunity.

Authors:  Arnaud Pommier; Bruno Lucas; Armelle Prévost-Blondel
Journal:  Oncoimmunology       Date:  2013-10-09       Impact factor: 8.110

10.  Nitric Oxide Synthase 2 Improves Proliferation and Glycolysis of Peripheral γδ T Cells.

Authors:  Laetitia Douguet; Julien Cherfils-Vicini; Lloyd Bod; Renée Lengagne; Eric Gilson; Armelle Prévost-Blondel
Journal:  PLoS One       Date:  2016-11-03       Impact factor: 3.240

View more
  4 in total

Review 1.  γδ T cells: pleiotropic immune effectors with therapeutic potential in cancer.

Authors:  Bruno Silva-Santos; Sofia Mensurado; Seth B Coffelt
Journal:  Nat Rev Cancer       Date:  2019-07       Impact factor: 60.716

Review 2.  Metabolic Changes in Tumor Microenvironment: How Could They Affect γδ T Cells Functions?

Authors:  Anna Maria Corsale; Marta Di Simone; Elena Lo Presti; Carmela Picone; Francesco Dieli; Serena Meraviglia
Journal:  Cells       Date:  2021-10-26       Impact factor: 6.600

Review 3.  γδ T cells in cancer: a small population of lymphocytes with big implications.

Authors:  Mathilde Raverdeau; Stephen P Cunningham; Cathal Harmon; Lydia Lynch
Journal:  Clin Transl Immunology       Date:  2019-10-10

4.  Myeloid-Derived Suppressor Cells and γδT17 Cells Contribute to the Development of Gastric MALT Lymphoma in H. felis-Infected Mice.

Authors:  Yanan Zhao; Fei Lu; Jingjing Ye; Min Ji; Yihua Pang; Yan Wang; Lingbo Wang; Guosheng Li; Tao Sun; Jingxin Li; Daoxin Ma; Chunyan Ji
Journal:  Front Immunol       Date:  2020-01-28       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.